This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Fat Loss Stack
Appetite Suppression / Fat Oxidation / Passive Thermogenesis / Lean Mass Preservation
Overview
What is Fat Loss Stack?
Scientific Sean's recommended fat loss research stack, layering a GLP-1 (Tirzepatide preferred, with Semaglutide and Retatrutide as alternatives) for appetite suppression with Cardarine (PPARδ agonist) and Injectable L-Carnitine to flip the body to fat-as-fuel, plus Mirabegron (β3 agonist) for passive thermogenesis. Optional add-ons — 5-Amino-1MQ, MOTS-C, and SLU-PP-332 — layer in mitochondrial and exercise-mimetic effects for deeper or more experienced cuts. Built on the explicit assumption that sleep, diet, exercise, and habits are already dialed in; calorie deficit remains the actual driver.
Key Benefits
Reduced cravings and hunger from GLP-1, forced fat-as-fuel substrate switching from Cardarine + L-Carnitine, ~100-300 extra passive calories/day burned via Mirabegron's brown-adipose activation and mitochondrial uncoupling, improved insulin sensitivity, glycogen sparing, and steadier energy through a deficit. Optional add-ons push mitochondrial efficiency (5-Amino-1MQ, MOTS-C) and exercise-mimetic metabolic upregulation (SLU-PP-332). Lean mass preservation is the core design goal — Sean explicitly warns against rushing the rate of loss.
Mechanism of Action
Multi-pathway fat loss convergence. GLP-1s (Sema/Tirz/Reta) suppress appetite via central GLP-1 receptor agonism, dropping caloric intake into deficit. Cardarine activates PPARδ in skeletal muscle, upregulating fatty-acid oxidation enzymes and forcing the body to prefer fat over glycogen as fuel. Injectable L-Carnitine supplies the mitochondrial shuttle (CPT-1/CPT-2) needed to actually transport long-chain fatty acids into the mitochondrial matrix — Cardarine sets the preference, L-Carnitine permits the oxidation. Mirabegron agonizes β3-adrenoceptors on brown adipose tissue, driving UCP1-mediated mitochondrial uncoupling and passive heat/calorie expenditure. 5-Amino-1MQ inhibits NNMT to preserve intracellular NAD+ and SAM, boosting mitochondrial efficiency in adipocytes. MOTS-C (mitochondrial-derived peptide) activates AMPK to shift the cell toward fuel-burning over storage. SLU-PP-332 is an ERR (estrogen-related receptor) agonist mimicking exercise-induced metabolic adaptations.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.